title: Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.
abstract: We report the results of intravenous anti-D (WinRho, WinRho SD) therapy in 261 non-splenectomized patients treated at the New York Hospital-Cornell Medical Center over the period from 1987 to 1994. Children (n = 124) and adult patients (n = 137) with classic immune thrombocytopenic purpura (ITP; n = 156) or human immunodeficiency virus (HIV) related thrombocytopenia (n = 105) and acute (n = 75) or chronic (n = 186) disease at the time of the initial anti-D treatment were studied. In addition, 11 previously splenectomized patients were treated as a separate group. Our objectives were to evaluate the following. (1) Efficacy of anti-D: The response after the initial infusion was analyzed according to clinical parameters, such as patient's age, HIV status, gender, disease duration, pretreatment platelet count, and hemoglobin value, as well as treatment-related factors, including the dose of anti-D, the solvent detergent treatment of the preparation, and the type of administration. (2) Use of anti-D as maintenance therapy: The duration of response after the initial infusion and the results of subsequent treatments were evaluated. (3) Safety/toxicity of anti-D: Postinfusion reactions and hemoglobin decrease after treatment were studied. Anti-D is a safe treatment providing a hemostatic platelet increase in greater than 70% of the Rh+ non-splenectomized patients. The group with the best results is HIV- children, but all patient groups respond and the effect lasts more than 21 days in 50% of the responders. Duration of response is not influenced by HIV status; furthermore, HIV+ patients show no adverse effects on hemoglobin decrease or HIV disease progression. Patients with chronic ITP after splenectomy have minimal or no response to intravenous anti-D.
authors.affiliation: Department of Pediatrics, The New York Hospital-Cornell Medical Center, New York, NY 10021, USA.
authors.forename: A
authors.initials: A
authors.lastname: Scaradavou
authors.forename: B
authors.initials: B
authors.lastname: Woo
authors.forename: B M
authors.initials: BM
authors.lastname: Woloski
authors.forename: S
authors.initials: S
authors.lastname: Cunningham-Rundles
authors.forename: L J
authors.initials: LJ
authors.lastname: Ettinger
authors.forename: L M
authors.initials: LM
authors.lastname: Aledort
authors.forename: J B
authors.initials: JB
authors.lastname: Bussel
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018450:Disease Progression; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D015658:HIV Infections / Q000150:complications; D006461:Hemolysis / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000276:immunology / Q000628:therapy*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage / Q000627:therapeutic use*; D012449:Safety; D013156:Splenectomy; D016896:Treatment Outcome
chemical_list: D018029:Rho(D) Immune Globulin